Madrigal Pharmaceuticals, Inc. MDGL
Updated: 7 Sep 2026
No signal published yet
We already track Madrigal Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Madrigal Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Madrigal Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 30, 2026, Madrigal reported its second-quarter 2026 financial results, posting Rezdiffra net revenues of $364.3 million. The company recorded a net loss of $57.9 million for the quarter while strengthening its patent portfolio with three new resmetirom patents. On September 2, 2026, Madrigal announced its participation in the Cantor Global Healthcare Conference.
What Firelda Watch includes for Madrigal Pharmaceuticals, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Madrigal Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Madrigal Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more